ADC Therapeutics SA financial data

Symbol
ADCT on NYSE
Industry
Pharmaceutical Preparations
Location
Biopole, Route De La Corniche 3 B, Epalinges, Switzerland
State of incorporation
Switzerland
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 478 %
Quick Ratio 24.4 %
Debt-to-equity -293 % +69.7%
Return On Equity 90.1 % -80.9%
Return On Assets -46.7 % +12.5%
Operating Margin -184 % +22.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 99.1M shares +20.1%
Common Stock, Shares, Outstanding 98.9M shares +20.1%
Entity Public Float 173M USD +13%
Common Stock, Value, Issued 8.43M USD +15.2%
Weighted Average Number of Shares Outstanding, Basic 97.2M shares +18.9%
Weighted Average Number of Shares Outstanding, Diluted 97.2M shares +18.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 70.8M USD +1.84%
Revenue from Contract with Customer, Excluding Assessed Tax 69.5M USD +26.3%
Research and Development Expense 110M USD -13.8%
Selling and Marketing Expense 44M USD -23.4%
General and Administrative Expense 41.9M USD -13.5%
Costs and Expenses 201M USD -14.5%
Operating Income (Loss) -131M USD +21.3%
Nonoperating Income (Expense) -25.5M USD +13.4%
Income Tax Expense (Benefit) 166K USD -99.6%
Net Income (Loss) Attributable to Parent -158M USD +34.2%
Earnings Per Share, Basic -1.62 USD/shares +44.9%
Earnings Per Share, Diluted -1.62 USD/shares +44.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 251M USD -9.95%
Inventory, Net 18.4M USD +13.7%
Other Assets, Current 9.45M USD +57.8%
Assets, Current 307M USD -8.59%
Deferred Income Tax Assets, Net 0 USD -100%
Property, Plant and Equipment, Net 5.08M USD -9.73%
Operating Lease, Right-of-Use Asset 8.35M USD -20.5%
Other Assets, Noncurrent 1.16M USD +63.3%
Assets 322M USD -9.25%
Accounts Payable, Current 18M USD +15.8%
Accrued Liabilities, Current 62.4M USD +19.8%
Liabilities, Current 80.5M USD +18.9%
Deferred Income Tax Liabilities, Net 1.91M USD +43.5%
Operating Lease, Liability, Noncurrent 8M USD -21.5%
Other Liabilities, Noncurrent 2.43M USD -72.6%
Liabilities 525M USD +4.29%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.42M USD -1428%
Retained Earnings (Accumulated Deficit) -1.49B USD -11.8%
Stockholders' Equity Attributable to Parent -203M USD -36.7%
Liabilities and Equity 322M USD -9.25%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.1M USD -186%
Net Cash Provided by (Used in) Financing Activities 356K USD -16.2%
Net Cash Provided by (Used in) Investing Activities -531K USD +47.7%
Common Stock, Shares, Issued 102M shares +14.1%
Common Stock, Par or Stated Value Per Share 0.08 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 251M USD -9.95%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.9M USD +5.01%
Deferred Tax Assets, Valuation Allowance 220M USD +3.62%
Deferred Tax Assets, Gross 222M USD +3.87%
Operating Lease, Liability 9.37M USD -19.6%
Depreciation 1.33M USD +12.4%
Payments to Acquire Property, Plant, and Equipment 531K USD -47.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -159M USD +34.2%
Lessee, Operating Lease, Liability, to be Paid 10.8M USD -20.7%
Property, Plant and Equipment, Gross 10.4M USD +5.03%
Operating Lease, Liability, Current 1.37M USD -6.54%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.68M USD -13.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.78M USD -8.95%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.47M USD -27%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.72M USD -13.1%
Deferred Tax Assets, Operating Loss Carryforwards 150M USD -7.95%
Unrecognized Tax Benefits 7.51M USD +13.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.76M USD -11.7%
Additional Paid in Capital 1.28B USD +8.75%
Deferred Tax Assets, Net of Valuation Allowance 1.91M USD +43.5%
Interest Expense 50.2M USD +8.39%